Last edition
News about "Moderna"
Moderna and Merck Show Durable Five-Year Benefit for Intismeran-KEYTRUDA in Melanoma
At a median five-year follow-up, intismeran autogene plus KEYTRUDA reduced recurrence or death risk by 49 percent versus KEYTRUDA alone, with further data expected and multiple late-stage trials ongoing across tumour types.
Moderna | 22/01/2026 | By News Bureau
XOMA Royalty to Acquire Generation Bio
The acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio’s collaboration with Moderna.
Moderna | 17/12/2025 | By News Bureau | 122
Moderna Onshores Full mRNA Drug Production to USA, Expands Norwood Facility
Moderna, Inc. announced a major expansion of its U.S. manufacturing operations by bringing drug product manufacturing to its Moderna Technology Center (MTC) in Norwood, Massachusetts. With this onshoring move, the company will now manage complete end-to-end manufacturing for its mRNA medicines within the United States.
Moderna | 21/11/2025 | By Darshana | 152
Moderna Opens mRNA Vaccine Manufacturing Facility in the UK
The Moderna Innovation and Technology Centre (MITC) has officially opened at the Harwell Science and Innovation Campus in Oxfordshire, becoming the UK’s first facility to manufacture an onshore supply of mRNA vaccines.
Moderna | 25/09/2025 | By Dineshwori | 109
Moderna Sees 41 Percent Q2 Revenue Drop as COVID Vaccine Sales Decline
Moderna posted USD 142 million in revenue for the second quarter 2025, down 41 percent from USD 241 million in the same period last year.
Moderna | 04/08/2025 | By Dineshwori | 219
Moderna reports positive results from phase 3 efficacy study of P304 for seasonal influenza vaccine
In a previous phase 3 study, mRNA-1010 had already demonstrated superior seroconversion rates and geometric mean titer ratios (GMR) against all strains included in the vaccine compared to both high-dose and standard-dose licensed seasonal influenza vaccine.
Moderna | 02/07/2025 | By Darshana | 240
Moderna Gets MHRA Authorization for Updated COVID-19 Vaccine
For the first time in the UK, the updated vaccine, Spikevax JN.1, will also be available to purchase privately for those who are not eligible for the NHS Autumn vaccination program.
Moderna | 05/09/2024 | By Aishwarya | 386
Moderna and Mitsubishi Tanabe Pharma to Promote mRNA Respiratory Vaccine in Japan
Moderna, Inc. has signed a joint agreement with Mitsubishi Tanabe Pharma regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including Moderna's COVID-19 vaccine, Spikevax.
Moderna | 15/07/2024 | By Aishwarya | 529
Global diseases treatment with mRNA to be researched by Moderna and IAVI together
Moderna and IAVI, a nonprofit scientific research organization, are teaming up to use mRNA to develop new therapies for a range of diseases like HIV / AIDS, Tuberculosis, anti-microbial-resistant enteric infection and COVID-19.
Moderna | 12/04/2022 | By Sudeep Soparkar | 671
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy